Torrent Pharmaceuticals revenue and financials
₹4,772.00Change from previous close: 0.00%
In the fiscal year ended March 2026, Torrent Pharmaceuticals reported revenue of ₹137.53B (+21.52% year over year). Net income was ₹21.63B, a net margin of 15.7%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +21.52%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +13.19%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 15.7%
- FY to Mar 2025: 16.9%
Financial data
Amounts in millions of INR; per-share values in INR; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 |
|---|---|---|---|---|
| Total revenue | 137,530 | 113,173 | 105,623 | 94,637 |
| Cost of revenue | 35,251 | 28,845 | 27,877 | 28,277 |
| Gross profit | 102,279 | 84,328 | 77,746 | 66,360 |
| Selling, general and administrative | 23,921 | 19,989 | 19,020 | 16,408 |
| Research and development | 450 | 304 | 247 | 313 |
| Operating income | 34,398 | 29,261 | 25,724 | 21,400 |
| EBIT | 32,569 | 29,242 | 27,047 | 21,794 |
| EBITDA | 43,758 | 37,191 | 35,000 | 28,814 |
| Interest expense | 3,847 | 2,514 | 3,526 | 3,322 |
| Pre-tax income | 28,722 | 26,728 | 23,521 | 18,472 |
| Income tax | 7,340 | 7,616 | 6,957 | 6,019 |
| Net income | 21,634 | 19,113 | 16,564 | 12,452 |
| Net income to common shareholders | 21,634 | 19,113 | 16,564 | 12,452 |
| Basic EPS | 63.92 | 56.47 | 48.94 | 36.79 |
| Diluted EPS | 63.92 | 56.47 | 48.94 | 36.79 |
| Average shares (basic) | 338 | 338 | 338 | 338 |
| Average shares (diluted) | 338 | 338 | 338 | 338 |